Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials
Romero J, Díaz J, Grushko M, Quispe R, Briceno D, Avendano R, Golive A, Pina I, Natale A, Garcia M, Jorde U, Di Biase L. Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials. EP Europace 2017, 20: f211-f216. PMID: 29161424, DOI: 10.1093/europace/eux324.Peer-Reviewed Original ResearchConceptsNon-ischemic cardiomyopathyImplantable cardioverter defibrillatorCause mortalityNICM patientsPrimary ProphylacTic Implantable Cardioverter DefibrillatorsRole of ICDUse of ICDsTotal mortalityProphylactic implantable cardioverter defibrillatorProspective randomized clinical trialsCardiac resynchronization therapy pacemakerCause mortality benefitProphylactic ICD placementMedical therapy groupRandomized clinical trialsRandom-effects modelSignificant reductionFixed-effects modelMean followMortality benefitICD groupIschemic cardiomyopathyMedical therapyICD placementTreatment arms